Business
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Adam Zaeske as Executive Vice
About this update from Harmony Biosciences Holdings, Inc.
[{"type":"text","content":" PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--\nHarmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025. The company’s current CCO, Jeffrey Dierks, is voluntarily stepping down for personal reasons.\n\nZaeske brings 25 years of global leadership across the pharmaceutical industry, building teams and transforming organizations in both the U.S. and Europe. He has broad functional experience spanning commercial strategy and operations, sales, marketing, market access, new product planning and finance. At Harmony, Zaeske will be responsible for leading the company’s commercial organization, setting commercial strategy, driving market expansion in the U.S. and abroad, and ensuring strong execution across all brands and geographies. His deep expertise in launching products, including in rare diseases, coupled with his extensive experience in scaling commercial operations and embedding strong capabilities, will be pivotal as Harmony builds on the commercial success of WAKIX® (pitolisant) and prepares to advance its late-stage pipeline assets toward approvals both in the U.S. and other territories to serve even more patients worldwide.\n\n“I am very excited to welcome Adam to the team as we build upon the commercial success of WAKIX in narcolepsy and prepare for our next phase of growth,” said Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences. “As Harmony continues to execute on our growth strategy, Adam’s deep commercial expertise, proven leadership across both the US and international markets, and experience launching and growing brands, including in rare diseases, make him the ideal person to lead our Commercial team and drive our next phase of growth. I also want to express my gratitude to Jeffrey Dierks for his contributions in building Harmony’s strong commercial foundation and leading the successful launch and commercialization of WAKIX. With this foundation, we remain confident in our 2025 revenue guidance and in WAKIX being a $1B plus opportunity in adult narcolepsy alone.”\n\nZaeske most recently served as Head of Central, South, and Eastern Europe at Takeda Pharmaceuticals, where he managed a $2 billion business spanning 25 countries and nearly 900 employees. Under hi...